| Circular RNA and its mechanisms in disease: From the bench to the clinic |
92 |
| Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities |
87 |
| Biogenesis and function of extracellular vesicles in cancer |
70 |
| Sirtuin activators and inhibitors: Promises, achievements, and challenges |
59 |
| EMT: Mechanisms and therapeutic implications |
57 |
| Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas |
51 |
| Targeting Programmed Cell Death-1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy |
46 |
| Post-stroke depression: Mechanisms and pharmacological treatment |
46 |
| DNA mismatch repair in cancer |
43 |
| The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives |
41 |
| Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response |
40 |
| The neuropsychopharmacology of cannabis: A review of human imaging studies |
38 |
| Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment |
38 |
| ROCK inhibition in models of neurodegeneration and its potential for clinical translation |
35 |
| Oxidative stress and cellular pathways of asthma and inflammation: Therapeutic strategies and pharmacological targets |
35 |
| TSPO in diverse CNS pathologies and psychiatric disease: A critical review and a way forward |
34 |
| ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway |
33 |
| Vitamin C for the treatment of sepsis: The scientific rationale |
31 |
| Therapeutic potential of omega-3 fatty acid-derived epoxyeicosanoids in cardiovascular and inflammatory diseases |
31 |
| Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection |
30 |
| Recent advances in the development of Mcl-1 inhibitors for cancer therapy |
30 |
| Cannabis use during pregnancy: Pharmacokinetics and effects on child development |
30 |
| Autism Spectrum Disorder: Classification, diagnosis and therapy |
29 |
| A review of bispecific antibodies and antibody constructs in oncology and clinical challenges |
28 |
| Autophagy as an emerging target in cardiorenal metabolic disease: From pathophysiology to management |
28 |
| Two decades of research in discovery of anticancer drugs targeting STAT how close are we? |
28 |
| The role of DNA methylation in epigenetics of aging |
26 |
| The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation? |
26 |
| The Hippo pathway in normal development and cancer |
25 |
| Emerging tumor spheroids technologies for 3D in vitro cancer modeling |
24 |
| Senescence and senotherapeutics: a new field in cancer therapy |
24 |
| Bispecific antibodies for cancer therapy: A review |
24 |
| Mitochondrial Ca2+ signaling |
23 |
| Recent therapeutic trends and promising targets in triple negative breast cancer |
23 |
| Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function |
23 |
| Inflammasome biology, molecular pathology and therapeutic implications |
23 |
| RNA therapy: Are we using the right molecules? |
22 |
| Targeting indoleamine-3-dioxygenase in cancer: Scientific rationale and clinical evidence |
22 |
| Hypoxia inducible factor as a therapeutic target for atherosclerosis |
22 |
| Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies |
22 |
| ATM in DNA repair in cancer |
22 |
| Effect fingerprinting of new psychoactive substances (NPS): What can we learn from in vitro data? |
22 |
| The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease |
22 |
| Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences |
21 |
| Paving the Rho in cancer metastasis: Rho GTPases and beyond |
21 |
| Toll-like receptors and their role in persistent pain |
21 |
| Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer |
20 |
| Gene-environment interactions in Alzheimer's disease: A potential path to precision medicine |
20 |
| Vitamin A signaling and homeostasis in obesity, diabetes, and metabolic disorders |
20 |
| The role of flavonoids in autoimmune diseases: Therapeutic updates |
20 |
